Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

14. Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Movement Disorders. 2017;32(9):1264–1310; Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862.

15. Osler W, Sir. The Principles and Practice of Medicine. New York: D. Appleton and Company; 1892.

16. Carlsson A. Nobel lecture: a half-century of neurotransmitter research: impact on neurology and psychiatry. Bioscience Reports . 2001;21(6):691–710.

17 Там же; Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.

18. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.

19. Carlsson A. Nobel lecture: a half-century of neurotransmitter research: impact on neurology and psychiatry. Bioscience Reports. 2001;21(6):691–710.

20. Hagerty JR. Arvid Carlsson, snubbed at University in Sweden, found a path to Nobel Prize in medicine. Wall Street Journal. July 13, 2018.

21. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences. 1973;20(4):415–455.

22. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.

23. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell and Tissue Research. 2004;318(1): 121–134; Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). Journal of Neurology . 2002;249(3):iii1-iii5.

24. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurology . 2006;5(3):235–245; Park A, Stacy M. Non-motor symptoms in Parkinson’s disease. Journal of Neurology . 2009;256(3):293–298.

25. Schrag A. Quality of life and depression in Parkinson’s disease. Journal of the Neurological Sciences. 2006;248(1):151–157; Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Movement Disorders . 2001;16(3):507–510; Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Movement Disorders . 2011;26(3):399–406.

26. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.

27. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862; Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wiener klinische Wochenschrift. 1961;73:787–788.

28. Cotzias GC. L-dopa for Parkinsonism. New England Journal of Medicine. 1968;278(11):630; Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism – chronic treatment with L-dopa. New England Journal of Medicine. 1969;280(7):337–345; Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Archives of Neurology. 1969;21(4):343–354.

29. Sacks O. Awakenings. Rpt. ed. Vintage; 1999./ Оливер Сакс «Пробуждения»

30. Parkinson J. An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223–236.

31. Osler W, Sir. The Principles and Practice of Medicine. D. Appleton and Company; 1892.

32. Langston JW. The MPTP story. Journal of Parkinsons Disease. 2017;7(s1):S11-S19.

33. Там же.

34. Langston JW, Palfreman J. The Case of the Frozen Addicts: How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinsons Disease. Rev. ed. IOS Press; 2014.

35. Langston JW. The MPTP story. Journal of Parkinsons Disease. 2017;7(s1):S11-S19; Nonnekes J, Post B, Tetrud JW, Langston JW, Bloem BR. MPTP-induced parkinsonism: an historical case series. Lancet Neurology . 2018;17(4):300–301.

36. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science . 1983;219(4587):979–980.

37. “NOVA; case of the frozen addict, the.” OpenVault from WGBH Boston/ BBC TV. February 18, 1986. http://openvault.wgbh.org/catalog/V_474C F2C8A20B4173988486AC4C605A3C. At 00:55:25.

38. Cervone C. Frozen addicts; drug addicts developed Parkinson’s disease. Las Vegas World News . December 9, 2013. www.lasvegasworldnews. com/frozen-addicts-drug-addicts-developed-parkinsons-disease/14976. Accessed December 13, 2018.

39. Desmethylprodine. Wikipedia. https://en.wikipedia.org/wiki/ Desmethylprodine. Updated December 31, 2018. Accessed March 31, 2019.

40. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry. 1992;55(3):181–184.

41. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research. 1979;1(3):249–254.

42. Там же.

43. Designer drugs: hearing before the Committee on the Budget, United States Senate, Ninety-Ninth Congress, first session, July 18, 1985. US Government Publishing Office; 1985.

44. Там же.

45. Sinclair M. Tragedy has designer label. Washington Post. July 19, 1985.

46. Там же.

47. Langston JW, Palfreman J. The Case of the Frozen Addicts: How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinsons Disease. Rev. ed. IOS Press; 2014.

48. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research. 1979;1(3):249–254.

49. Там же.

50. Langston JW, Palfreman J. The Case of the Frozen Addicts: How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinsons Disease. Rev. ed. IOS Press; 2014.

51. Designer drugs: hearing before the Committee on the Budget, United States Senate, Ninety-Ninth Congress, first session, July 18, 1985. US Government Publishing Office; 1985.

52. Sinclair M. Tragedy has designer label. Washington Post. July 19, 1985.

53. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research . 1979;1(3):249–254.

54. Designer drugs: hearing before the Committee on the Budget, United States Senate, Ninety-Ninth Congress, first session, July 18, 1985. US Government Publishing Office; 1985.

55. Langston JW. The MPTP story. Journal of Parkinsons Disease. 2017;7(s1):S11-S19.

56. Там же.

57. Goldman SM. Environmental toxins and Parkinson’s disease. Annual Review of Pharmacology and Toxicology. 2014;54(1):141–164; Betarbet R, Sherer TB, Mackenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience. 2000;3(12):1301–1306; Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson’s disease and brain levels of organochlorine pesticides. Annals of Neurology . 1994;36(1):100–103; Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta– analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology . 2000;21(4):435–440.